OBJECTIVE:To analyze the impact of model for end‐stage liver disease (MELD) allocation policy on survival outcomes after liver transplantation (LT).INTRODUCTION:Considering that an ideal system of grafts allocation should also ensure improved survival after transplantation, changes in allocation policies need to be evaluated in different contexts as an evolutionary process.METHODS:A retrospective cohort study was carried out among patients who underwent LT at the University of Pernambuco. Two groups of patients transplanted before and after the MELD allocation policy implementation were identified and compared using early postoperative mortality and post‐LT survival as end‐points.RESULTS:Overall, early postoperative mortality did not significantly differ between cohorts (16.43% vs. 8.14%; p = 0.112). Although at 6 and 36‐months the difference between pre‐ vs. post‐MELD survival was only marginally significant (p = 0.066 and p = 0.063; respectively), better short, medium and long‐term post‐LT survival were observed in the post‐MELD period. Subgroups analysis showed special benefits to patients categorized as non‐hepatocellular carcinoma (non‐HCC) and moderate risk, as determined by MELD score (15‐20).DISCUSSION:This study ensured a more robust estimate of how the MELD policy affected post‐LT survival outcomes in Brazil and was the first to show significantly better survival after this new policy was implemented. Additionally, we explored some potential reasons for our divergent survival outcomes.CONCLUSION:Better survival outcomes were observed in this study after implementation of the MELD criterion, particularly amongst patients categorized as non‐HCC and moderate risk by MELD scoring. Governmental involvement in organ transplantation was possibly the main reason for improved survival.
. We used analysis of area under ROC (receiver operating characteristic) as a summary measure of the performance of the MELD score and assessed predictors of medium-term survival using univariate and multivariate analysis. Results Results ResultsResults Results: The cumulative survival of three, six, 12 and 24 months of the 208 patients studied was 85.1%, 79.3%, 74.5% and 71.1%, respectively. The preoperative MELD score showed a low discriminatory power for predicting survival after TH. By univariate analysis, we identified intraoperative transfusion of red blood cells (p <0.001) and platelets (p = 0.004) and type of venous hepatocaval anastomosis (p = 0.008) as significantly related to medium-term survival of the patients studied. However, by multivariate analysis only red blood cell transfusion was a significant independent predictor of outcome. Conclusion Conclusion Conclusion Conclusion Conclusion: The MELD score showed low overall accuracy for predicting post-transplant survival of patients studied, among which only intraoperative transfusion of red blood cells was identified as an independent predictor of survival in the medium term after TH.
PURPOSE:To explore the effect of acute kidney injury (AKI) on long-term survival after conventional orthotopic liver transplantation (OLT) without venovenous bypass (VVB). METHODS: A retrospective cohort study was carried out on 153 patients with end-stage liver diseases transplanted by the Department of General Surgery and Liver Transplantation of the University of Pernambuco, from August, 1999 to December, 2009. The KaplanMeier survival estimates and log-rank test were applied to explore the association between AKI and long-term patient survival, and multivariate analyses were applied to control the effect of other variables. RESULTS: Over the 12.8-year follow-up, 58.8% patients were alive with a median follow-up of 4.5-year. Patient 1-, 2-, 3-and 5-year survival were 74.5%, 70.6%, 67.9% and 60.1%; respectively. Early postoperative mortality was poorer amongst patients who developed AKI (5.4% vs. 20%, p=0.010), but long-term 5-year survival did not significantly differed between groups (51.4% vs. 65.3%; p=0.077). After multivariate analyses, AKI was not significantly related to long-term survival and only the intraoperative transfusion of red blood cells was significantly related to this outcome (non-adjusted Exp[b]=1.072; p=0.045). CONCLUSION: The occurrence of postoperative acute kidney injury did not independently decrease patient survival after orthotopic liver transplantation without venovenous bypass in this data from northeast Brazil. Key words: Liver Transplantation. Renal Insufficiency. Prognosis RESUMO OBJETIVO: Explorar o efeito da insuficiência renal aguda (IRA) na sobrevivência de longo prazo após o transplante hepático convencional ortotópico (THC) sem desvio venovenoso (DVV). MÉTODOS: Estudo de coorte retrospectivo envolvendo153 pacientes portadores de doença hepática terminal transplantados pelo Departamento de Cirurgia Geral e Transplante Hepático da Universidade de Pernambuco, no período de agosto de 1999 a dezembro de 2009. O método de Kaplan-Meier e o teste log-rank foram aplicados para explorar a associação entre o IRA com a sobrevivência de longo prazo dos pacientes, aplicando-se o modelo multivariado de riscos proporcionais de Cox para controlar o efeito de outras variáveis. RESULTADOS: A proservação atingiu 12,8 anos, durante a qual 58,8% dos pacientes permaneceram vivos com mediana de acompanhamento de 4,5 anos. As taxas de sobrevivência cumulativa de 1 -, 2 -, 3 -e 5 anos foram de 74,5%, 70,6%, 67,9% e 60,1%; respectivamente. A taxa de mortalidade pós-operatória precoce foi maior entre os pacientes que desenvolveram IRA (5,4% vs. 20%, p = 0,010), mas a sobrevivência de longoprazoem5 anos não diferiu significativamente entre os grupos (51,4% vs. 65,3%, p = 0,077). Após análise multivariada, a IRA nãofoisignificativamenterelacionado à sobrevivência a longo prazo e apenas transfusão intra-operatório de hemácias foi significativamente relacionado com este desfecho (Exp [b] não-ajustado = 1,072, p = 0,045). CONCLUSÃO: A ocorrência de insuficiência renal aguda pós-operatória não d...
InTRODUÇÃOLesão por isquemia e reperfusão é processo inevitável que culmina com morte celular e afeta muito a função do enxerto após o transplante de fígado . Em seguida à restauração do fluxo sangüíneo, o fígado é submetido a lesão adicional mais grave do que a induzida pela isquemia . Disfunção primária e a sua forma mais grave, a falência primária, são conseqüências da lesão de isquemia e reperfusão e representam importante causa no aumento da morbidade e mortalidade após transplante de fígado 3 .O uso de enxertos marginais tem sido solução aceita pela escassez de órgãos para transplante e o seu uso tornou-se muito comum em todo mundo. A literatura vem mostrando efetividade desses órgãos e seus resultados no transplante de fígado 4,5,6 .O objetivo deste estudo é apresentar a experiência com transplante de fígado utilizando órgãos de doadores marginais em um centro hospitalar. ABCDDV/580
OLT without VVB can be safely performed even in severe cases of chronic liver failure.
PURPOSE:To explore non-cancerous factors that may be related with medium-term survival (24 months) after liver transplantation (LT) in this data from northeast Brazil. METHODS:A cross-sectional study was carried out in patients who underwent deceased-donor orthotopic LT because hepatocellular carcinoma (HCC) at the University of Pernambuco, Brazil. Non-cancerous factors (i.e.: donor-, receptor-, surgery-and center-related variables) were explored as prognostic factors of medium-term survival using univariate and multivariate approachs. RESULTS:Sixty-one patients were included for analysis. Their three, six, 12 and 24-month overall cumulative survivals were 88.5%, 80.3%, 73.8% and 65.6%, respectively. Our univariate analysis identified red blood cell transfusion (Exp[b]=1.26; p<0.01) and hepatovenous reconstruction technique (84.6% vs. 51.4%, p<0.01; respectively for piggyback and conventional approaches) as significantly related to post-LT survival. The multivariate analysis confirmed the hepato-venous reconstruction technique was an independent prognostic factor. CONCLUSION:The piggyback technique was related to improved medium-term survival of hepatocellular carcinoma patients after liver transplantation in this northeast Brazilian sample.Key words: Organ Transplantation. Liver Neoplasms. Carcinoma, Hepatocellular. Survival Analysis. Prognosis. RESUMO OBJETIVO:Explorar fatores prognósticos não oncológicos para a sobrevivência de médio prazo (24 meses) de portadores de carcinoma hepatocelular tratados com transplante hepático. MÉTODOS: Estudo de corte incluindo pacientes submetidos a transplante ortotópico de fígado (doador-cadáver) pelo Serviço deCirurgia Geral e Transplante Hepático da Universidade de Pernambuco, UPE. Exploraram-se variáveis relacionadas ao doador, receptor, procedimento cirúrgico e serviço transplantador, como potenciais fatores prognósticos para a sobrevivência de médio prazo dos transplantados, aplicando-se análise uni e multivariada. Non-cancerous prognostic factors of hepatocellular carcinoma after liver transplantationActa Cirúrgica Brasileira -Vol. 27 (6) 2012 -397 RESULTADOS: Sessenta e um pacientes foram incluídos para análise. A sobrevivência cumulativa de três, seis, 12 e 24 meses observada foi de 88,5%, 80,3%, 73,8% e 65,6%, respectivamente. Por análise univariada, identificou-se a transfusão de hemácias (Exp[b]=1,26; p<0,01) e técnica cirúrgica empregada (84,6% vs. 51,4%, p<0,01; respectivamente, piggyback vs. convencional) como estatisticamente relacionadas à sobrevivência dos pacientes estudados. Por análise multivariada, confirmou-se a técnica empregada como fator prognóstico independente. CONCLUSÃO:A técnica cirúrgica piggyback se relacionou a melhor sobrevivência de médio prazo de pacientes com carcinoma hepatocelular após transplante de fígado nesta casuística do nordeste Brasileiro.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
334 Leonard St
Brooklyn, NY 11211
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.